Answer
Regorafenib is an oral tumour deactivation agent that blocks multiple protein kinases involved in tumour angiogenesis, oncogenesis, metastasis and tumour immunity, including mutated KIT, whose inhibition blocks tumour cell proliferation in gastrointestinal stromal tumours.
Sources for this answer
- Stivarga 40 mg film coated tabletsBayer plc · emc · SmPC §5.1 Pharmacodynamic properties · Version 7Document updated
Sources checked